糖心视频logo

• Corporate
• R&D

• For Print
• July 1, 2024

糖心视频logo

糖心视频logo (Headquarters: Tokyo, CEO: Haruo Naito, “糖心视频logo”) announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. Based on the agreement, 糖心视频logo now owns all rights to FZEC and will solely conduct the global development and commercialization of the agent. 糖心视频logo will accelerate the development of the agent as a high priority with the hope to deliver it to patients as early as possible. 糖心视频logo plans to refund a part of the unused portion of the $200 million payment it received towards research and development expenses from Bristol Myers Squibb under the collaboration agreement and record the remaining as other income.

FZEC is 糖心视频logo’s first ADC and is composed of 糖心视频logo’s in-house developed farletuzumab, a humanized IgG1 monoclonal antibody that binds to the FRα, and 糖心视频logo’s in-house developed anticancer agent eribulin, using an enzymatically cleavable linker. Currently, three clinical studies are ongoing: 糖心视频logo’s Phase 1/2 study for solid tumors (NCT04300556), and Bristol Myers Squibb’s Phase 2 studies for ovarian, peritoneal and fallopian tube cancers () and non-small cell lung cancer ().

糖心视频logo positions oncology as a key franchise area and aims to contribute toward the cure of cancers by exploring the depths of human biology. FZEC development for refractory cancers is a testament of our dedication to addressing the unmet medical needs of patients with cancer. 糖心视频logo will make continuous efforts to increase the benefits provided to patients with cancer and their families.

Media Inquiries:

Public Relations Department,

糖心视频logo

+81-(0)3-3817-5120

銆赌銆赌

[Notes to Editors] 

1. 1. Farletuzumab ecteribulin (FZEC, formerly known as MORAb-202)

FZEC is 糖心视频logo’s first antibody drug conjugate (ADC) and that is composed of 糖心视频logo’s in-house developed farletuzumab, a humanized IgG1 monoclonal antibody that binds to the folate receptor alpha (FRα), and 糖心视频logo’s in-house developed anticancer agent eribulin, using an enzymatically cleavable linker. After FZEC enters the target FRα-positive cancer cells, it is thought that the linker is enzymatically cleaved, releasing eribulin from the antibody leading to its antitumor activity. When the anticancer agent and antibody components of an ADC are separated inside a targeted antigen-positive cancer cell, it is theorized that the released anticancer agent also has a bystander effect on neighboring antigen-negative cancer cells and the component cells of the tumor microenvironment. In pre-clinical studies, FZEC demonstrated a bystander effect*, with antitumor activity on the FRα-negative cancer cells surrounding the FRα-positive cancer cells.

The payload eribulin was the first in the halichondrin class of microtubule dynamics inhibitor. Structurally, eribulin is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai, and functions by inhibiting the growth phase of microtubule dynamics which prevents cell division. Eribulin has been approved in countries including Japan, the United States, China, in Europe and in Asia for use in the treatment of advanced breast cancer and liposarcoma (soft tissue sarcoma in Japan).

*Bystander effect: When the anticancer agent and antibody parts of an ADC are separated inside a targeted antigen-positive cancer cell, the released anticancer agent also affects neighboring antigen-negative cancer cells and the component cells of the cancer microenvironment.

 銆赌銆赌

• Full text